Literature DB >> 33648465

Construction of the optimization prognostic model based on differentially expressed immune genes of lung adenocarcinoma.

Yang Zhai1,2, Bin Zhao3,4, Yuzhen Wang1, Lina Li1, Jingjin Li5, Xu Li1, Linhan Chang6, Qian Chen7, Zijun Liao8.   

Abstract

BACKGROUND: Lung adenocarcinoma (LUAD) is the most common pathology subtype of lung cancer. In recent years, immunotherapy, targeted therapy and chemotherapeutics conferred a certain curative effects. However, the effect and prognosis of LUAD patients are different, and the efficacy of existing LUAD risk prediction models is unsatisfactory.
METHODS: The Cancer Genome Atlas (TCGA) LUAD dataset was downloaded. The differentially expressed immune genes (DEIGs) were analyzed with edgeR and DESeq2. The prognostic DEIGs were identified by COX regression. Protein-protein interaction (PPI) network was inferred by STRING using prognostic DEIGs with p value< 0.05. The prognostic model based on DEIGs was established using Lasso regression. Immunohistochemistry was used to assess the expression of FERMT2, FKBP3, SMAD9, GATA2, and ITIH4 in 30 cases of LUAD tissues.
RESULTS: In total,1654 DEIGs were identified, of which 436 genes were prognostic. Gene functional enrichment analysis indicated that the DEIGs were involved in inflammatory pathways. We constructed 4 models using DEIGs. Finally, model 4, which was constructed using the 436 DEIGs performed the best in prognostic predictions, the receiver operating characteristic curve (ROC) was 0.824 for 3 years, 0.838 for 5 years, 0.834 for 10 years. High levels of FERMT2, FKBP3 and low levels of SMAD9, GATA2, ITIH4 expression are related to the poor overall survival in LUAD (p < 0.05). The prognostic model based on DEIGs reflected infiltration by immune cells.
CONCLUSIONS: In our study, we built an optimal prognostic signature for LUAD using DEIGs and verified the expression of selected genes in LUAD. Our result suggests immune signature can be harnessed to obtain prognostic insights.

Entities:  

Keywords:  Immunogenomics; Lung adenocarcinoma; Optimization models; Prognosis; TCGA

Mesh:

Substances:

Year:  2021        PMID: 33648465      PMCID: PMC7923649          DOI: 10.1186/s12885-021-07911-8

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  66 in total

1.  Gene ontology: tool for the unification of biology. The Gene Ontology Consortium.

Authors:  M Ashburner; C A Ball; J A Blake; D Botstein; H Butler; J M Cherry; A P Davis; K Dolinski; S S Dwight; J T Eppig; M A Harris; D P Hill; L Issel-Tarver; A Kasarskis; S Lewis; J C Matese; J E Richardson; M Ringwald; G M Rubin; G Sherlock
Journal:  Nat Genet       Date:  2000-05       Impact factor: 38.330

2.  A MYC target long non-coding RNA GATA2-AS1 regulates non-small cell lung cancer growth.

Authors:  L Zhang; L Gao; M Shao; G Y Sun
Journal:  Neoplasma       Date:  2019-10-08       Impact factor: 2.575

3.  TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells.

Authors:  Taiwen Li; Jingyu Fan; Binbin Wang; Nicole Traugh; Qianming Chen; Jun S Liu; Bo Li; X Shirley Liu
Journal:  Cancer Res       Date:  2017-11-01       Impact factor: 12.701

4.  Endoglin (CD105) and SMAD4 regulate spheroid formation and the suppression of the invasive ability of human pancreatic cancer cells.

Authors:  Eri Kokaji; Akiko Shimomura; Takashi Minamisaka; Takahiko Nakajima; Shigeharu Miwa; Hideki Hatta; Takeshi Nishida; Chieko Kiya; Johji Imura
Journal:  Int J Oncol       Date:  2018-02-01       Impact factor: 5.650

5.  Inflammatory Risk Factors for Early Recurrence of Non-Small Cell Lung Cancer Within One Year Following Curative Resection.

Authors:  Satoru Kobayashi; Yoko Karube; Yuji Matsumura; Morimichi Nishihira; Takashi Inoue; Osamu Araki; Sumiko Maeda; Masayuki Chida
Journal:  World J Surg       Date:  2020-10       Impact factor: 3.352

Review 6.  Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment.

Authors:  Sara Saab; Hussein Zalzale; Zahraa Rahal; Yara Khalifeh; Ansam Sinjab; Humam Kadara
Journal:  Front Immunol       Date:  2020-02-11       Impact factor: 7.561

7.  Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab.

Authors:  Tomoya Fukui; Shinji Hosotani; Itaru Soda; Takahiro Ozawa; Seiichiro Kusuhara; Mikiko I Kakegawa; Masashi Kasajima; Yasuhiro Hiyoshi; Satoshi Igawa; Masanori Yokoba; Hisashi Mitsufuji; Masaru Kubota; Masato Katagiri; Jiichiro Sasaki; Hiromichi Ishiyama; Katsuhiko Naoki
Journal:  Thorac Cancer       Date:  2020-02-14       Impact factor: 3.500

8.  Reduction of miR-744 delivered by NSCLC cell-derived extracellular vesicles upregulates SUV39H1 to promote NSCLC progression via activation of the Smad9/BMP9 axis.

Authors:  Liming Gao; Qi Tian; Tong Wu; Shanshan Shi; Xiaobo Yin; Lijie Liu; Lei Zheng; Ping Wang; Yaling Tian; Shufeng Xu
Journal:  J Transl Med       Date:  2021-01-20       Impact factor: 5.531

9.  FKBP3 mediates oxaliplatin resistance in colorectal cancer cells by regulating HDAC2 expression.

Authors:  Jiafeng Tong; Ying Shen; Xi Chen; Renjie Wang; Ye Hu; Xu Zhang; Zhenghua Zhang; Li Han
Journal:  Oncol Rep       Date:  2019-08-02       Impact factor: 3.906

Review 10.  New Frontiers for Molecular Pathology.

Authors:  Joanna Domagala-Kulawik
Journal:  Front Med (Lausanne)       Date:  2019-12-04
View more
  4 in total

1.  Identification of CDK2-Related Immune Forecast Model and ceRNA in Lung Adenocarcinoma, a Pan-Cancer Analysis.

Authors:  Ting-Ting Liu; Rui Li; Chen Huo; Jian-Ping Li; Jie Yao; Xiu-Li Ji; Yi-Qing Qu
Journal:  Front Cell Dev Biol       Date:  2021-07-30

2.  Identification of a 6-RBP gene signature for a comprehensive analysis of glioma and ischemic stroke: Cognitive impairment and aging-related hypoxic stress.

Authors:  Weiwei Lin; Qiangwei Wang; Yisheng Chen; Ning Wang; Qingbin Ni; Chunhua Qi; Qian Wang; Yongjian Zhu
Journal:  Front Aging Neurosci       Date:  2022-09-01       Impact factor: 5.702

3.  Proteomic alterations associated with residual disease in neoadjuvant chemotherapy treated ovarian cancer tissues.

Authors:  Emily R Penick; Nicholas W Bateman; Christine Rojas; Cuauhtemoc Magana; Kelly Conrads; Ming Zhou; Brian L Hood; Guisong Wang; Niyati Parikh; Ying Huang; Kathleen M Darcy; Yovanni Casablanca; Paulette Mhawech-Fauceglia; Thomas P Conrads; G Larry Maxwell
Journal:  Clin Proteomics       Date:  2022-10-04       Impact factor: 5.000

4.  Construction of mRNA prognosis signature associated with differentially expressed genes in early stage of stomach adenocarcinomas based on TCGA and GEO datasets.

Authors:  Fuquan Jiang; Haiguan Lin; Hongfeng Yan; Xiaomin Sun; Jianwu Yang; Manku Dong
Journal:  Eur J Med Res       Date:  2022-10-17       Impact factor: 4.981

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.